Teva Pharmaceutical's Q2 Report Sparks Significant Stock Surge
Teva Pharmaceutical (NYSE: TEVA) saw its stock rise approximately 12.3% in the last week of trading, outperforming both the S&P 500 and Nasdaq Composite indices. The surge followed Teva’s second-quarter earnings report released after market close on July 29, which showed mixed results but included positive developments that excited investors. While non-GAAP (adjusted) earnings came in at $0.02 per share—below the expected $0.11—the company exceeded revenue expectations with sales of $4.1 billion, surpassing analyst forecasts by about $70 million. Teva also announced a direct listing on the New York Stock Exchange for its common stock starting September 14, replacing American depositary receipts (ADRs), which is expected to attract institutional and retail investors. For fiscal year guidance, Teva projected adjusted earnings between $1.91 and $2.11 per share—slightly below analyst estimates—and sales in the range of $16.5 billion to $16.85 billion, close to Wall Street’s target.
Topics: financial_reporting pharmaceuticals stock_performance